English

• 13 Jan, 2022
  Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications
• 6 Dec, 2021
  Tumorad® shows good safety in preclinical studies
• 2 Dec, 2021
  Second dose group fully recruited in Spago Nanomedical’s phase 1 study with SpagoPix
• 10 Nov, 2021
  Spago Nanomedical interim report January-September 2021
• 10 Nov, 2021
  Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
• 21 Oct, 2021
  Nomination committee appointed for the 2022 Annual General Meeting in Spago Nanomedical
• 24 Aug, 2021
  Spago Nanomedical interim report January-June 2021
• 3 Aug, 2021
  Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer
• 5 May, 2021
  Bulletin from the 2021 Annual General Meeting of Spago Nanomedical AB (publ)
• 28 Apr, 2021
  Spago Nanomedical interim report January-March 2021